RESEARCH FIELD
3D197
Back3D197
3D197 is a next-generation fully human anti-CD47 IgG4 monoclonal antibody. We obtained IND approval for 3D197 from the NMPA in China in January 2022 to conduct studies to evaluate the efficacy of 3D197 in combination with envafolimab, azacitidine, rituximab and other combination therapies for solid tumors and hematologic malignancies.
